Information Provided By: 
Fly News Breaks for September 30, 2019
MRK, BLU
Sep 30, 2019 | 08:22 EDT
As previously reported, Guggenheim analyst Dana Flanders initiated Bellus Health (BLU) with a Buy rating and $12 price target. BLU-5937 for refractory chronic cough is the primary value driver in "a potential multi-billion dollar category," said Flanders, who also sees the opportunity for label expansion and the potential for M&A interest in Bellus. Merck (MRK) acquired Afferent, which also has a P2X3 antagonist asset called gefapixant, in 2016 for $500M upfront and up to $1.25B with milestones, noted Flanders.
News For BLU;MRK From the Last 2 Days
There are no results for your query BLU;MRK
